The FDA decision on the expanded use of Carvykti for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy is due on April 5, 2024.On March 15, 2024, an FDA panel recommended approval of the drug for the above-mentioned expanded indication. Janssen Biotech Inc., a Johnson & Johnson company, has an exclusive worldwide license and collaboration agreement with Legend Biotech to develop and commercialize Carvykti.The drug received its initial approval from the FDA in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.LEGN is currently (Mar.28, 2024) trading at $55.99, down 1.65%.